Trazodone: Discovery, Development, Safety and Pharmacovigilance
Trazodone is a triazolopyridine antidepressant developed in Italy in the 1960s. Its clinical story contains a persistent tension: an antidepressant authorised for depressive illness is now widely used in smaller doses for sleep, despite a substantially narrower evidence base for insomnia. Its sedating, serotonergic and alpha-adrenergic actions explain some therapeutic effects and several distinctive risks. Effective pharmacovigilance must distinguish the actual indication and dose from the authorised product indication, and must not treat a report of a low-dose bedtime prescription as evidence that trazodone is a licensed hypnotic [1–4].
- Trazodone: Discovery, Development, Safety and Pharmacovigilance
- Discovery, molecular design and early development
- Mechanism: receptor antagonism alongside serotonin uptake inhibition
- Pharmacokinetics and formulations
- Clinical evidence for depression
- Regulatory evolution and commercial history
- Insomnia: extensive use, limited authorisation and contested evidence
- Suicidality, mood switching and psychiatric context
- Cardiovascular safety: QT, syncope and falls
- Priapism: a distinctive serious risk
- Serotonin syndrome and interaction-driven toxicity
- Hyponatraemia and the 2025 safety-label update
- Bleeding, hepatic injury and additional risks
- Regional labelling and formulation-specific questions
- Pregnancy, lactation and special populations
- Pharmacovigilance cases: from observation to assessment
- Signal detection, risk governance and inspection readiness
- Practical review checklist
- Key takeaways
- References
- Regulatory Note
Discovery, molecular design and early development
Angelini Research Laboratories developed trazodone in Italy during the 1960s, before selective serotonin reuptake inhibitors became the dominant antidepressant class. The molecule is structurally unlike tricyclic antidepressants and has been described as a serotonin antagonist and reuptake inhibitor (SARI). Its pharmacological profile emerged from work on compounds affecting serotonergic transmission while avoiding some older antidepressant mechanisms [3,4]. The original historical accounts establish the company and decade, but do not justify attributing the molecule to an individual inventor without a specific primary patent or contemporaneous publication.
Trazodone reached the United States through Mead Johnson's Desyrel programme. The FDA approved the original tablet application, NDA 018207, on 24 December 1981 for major depressive disorder (MDD). The date is established both in FDA review documents and in a subsequent US appellate decision concerning the difference between the December 1981 approval and a February 1982 supplemental labelling action [5,6]. The litigation illustrates how approval dates, patent/exclusivity arguments and later marketing events must be kept separate in a pharmaceutical lifecycle narrative.
Mechanism: receptor antagonism alongside serotonin uptake inhibition
Trazodone inhibits serotonin reuptake and antagonises 5-HT2A receptors; additional receptor interactions include alpha-1 adrenergic and histamine H1 effects. The precise contribution of each action to antidepressant efficacy remains uncertain. FDA product information describes serotonergic enhancement as a plausible mechanism rather than a complete explanation of mood improvement [1,7]. Its receptor profile makes trazodone different from a typical high-selectivity SSRI, even though some regulatory labels classify it as a serotonin reuptake inhibitor.
The sedating properties that motivate off-label use do not establish antidepressant effectiveness at every low dose. Conversely, a drug can improve sleep in a person with depression without having demonstrated adequate efficacy as a treatment for primary chronic insomnia. A useful distinction is sedation as a pharmacological effect, sleep improvement as a measured clinical outcome, and an authorised insomnia indication—three different propositions.
Alpha-1 receptor antagonism contributes to orthostatic hypotension, while serotonergic actions help explain interactions and serotonin syndrome. Neither mechanism is sufficient to predict a particular patient's adverse-event risk without exposure, co-medications and clinical context.
Pharmacokinetics and formulations
Trazodone is absorbed after oral administration and extensively metabolised, primarily through CYP3A4 pathways. The metabolite meta-chlorophenylpiperazine (mCPP) has serotonergic activity. The US label advises considering dose changes when strong CYP3A4 inhibitors or inducers are introduced; central nervous system depressants can add to sedation and impaired performance [1,7]. These are interaction-management issues, not grounds for assuming that every concomitant prescription produced an adverse event.
Immediate-release tablets have traditionally been given in divided doses for depression. Controlled- and extended-release formulations were developed to provide a different concentration-time profile and permit once-daily administration. Different formulations can produce different peak exposures and administration instructions, even with the same active ingredient. Switching formulations without verifying the approved product's instructions may cause underdosing, oversedation or inadvertent dose escalation.
Clinical evidence for depression
Early immediate-release evidence
The US label states that trazodone's efficacy in MDD was established in inpatient and outpatient trials of the immediate-release formulation [1]. Historical trial methods, diagnostic criteria and comparator treatments differed from contemporary antidepressant programmes. Claims of comparative superiority should not be inferred from the mere fact of regulatory approval. Adverse-event comparisons also depend on dose, patient selection, trial duration and whether events were systematically sought.
Once-daily controlled-release pivotal trial
A multicentre, double-blind, placebo-controlled trial randomised 412 adults with MDD equally to trazodone Contramid once daily or placebo. Flexible doses of 150–375 mg/day were studied over eight weeks. The primary Hamilton Depression Rating Scale (HAM-D-17) improvement was −11.4 versus −9.3 points, with p=0.012 in the published analysis [8]. The difference is a group-level symptom-scale result, not proof of remission in every treated patient.
FDA's statistical review of NDA 022411 identified one pivotal phase III study and reported a primary analysis p-value of 0.0119. It also noted that secondary outcomes were not controlled for multiple testing [9]. This matters when interpreting claims about sleep, anxiety or individual depressive symptoms derived from the same trial: exploratory findings should not be promoted to independently proven indications.
Comparisons and negative evidence
Later studies compared various trazodone formulations with active antidepressants, including venlafaxine. A 2023 review summarises a noninferiority comparison of once-daily trazodone with venlafaxine XR and a placebo-controlled prolonged-release trial [10]. Trial-specific design and dose differences limit sweeping claims that trazodone is uniformly more effective or better tolerated. Some comparative trials found less favourable outcomes for trazodone on selected measures; the evidence does not support a simplistic winner across all depression phenotypes [11].
Regulatory evolution and commercial history
The original Desyrel product's US history was followed by generic formulations and a renewed interest in delivery systems. The FDA approved Oleptro, a once-daily extended-release formulation developed through Labopharm's Contramid technology, on 2 February 2010 for MDD in adults [9,12]. That approval did not transform the immediate-release tablet into a once-daily extended-release product or establish an insomnia indication.
The FDA approved Raldesy, trazodone hydrochloride oral solution 10 mg/mL, on 26 November 2024, also for MDD in adults, through NDA 218637. Its application relied in part on the agency's prior findings for Desyrel; it did not require a new independent pivotal depression-efficacy trial for the oral solution [13,14]. Oral solution introduces a distinct medication-error pathway: volume must be translated correctly into milligrams, and the correct dosing syringe and instructions matter.
Commercial history involves different entities at different stages—Angelini as originating developer, Mead Johnson for the early US product, Labopharm and partners for extended-release development, and later formulation-specific sponsors. No global revenue rank or attribution of combined company sales to trazodone is asserted here.
Insomnia: extensive use, limited authorisation and contested evidence
Trazodone is frequently prescribed at lower doses to help sleep, particularly when insomnia coexists with depression. That practice must be distinguished from an FDA-approved indication: US trazodone tablets and Raldesy are labelled for major depressive disorder in adults, not chronic insomnia [1,7]. The American Academy of Sleep Medicine's 2017 pharmacological guideline gave a weak recommendation against trazodone for sleep-onset or sleep-maintenance insomnia, based on one qualifying trial of 50 mg and effects judged below clinical importance thresholds [15]. This is a guideline recommendation, not a legal prohibition or a finding that trazodone never improves sleep.
The distinction matters for safety surveillance. In low-dose insomnia use, the person may have no depression, may be older, and may already take antihypertensives, hypnotics or alcohol. A dose that seems small relative to antidepressant treatment can still produce orthostatic symptoms, falls, arrhythmias or priapism. Clinical reports should record the actual indication and treatment objective rather than automatically coding every trazodone exposure as antidepressant treatment.
Suicidality, mood switching and psychiatric context
Current US trazodone labelling carries a boxed warning about increased suicidal thoughts and behaviours in paediatric and young adult patients in short-term antidepressant studies. Trazodone is not approved for paediatric patients in the United States [1]. Depression itself carries a risk of suicidality, so temporal association cannot establish that an event was drug-induced. The record should capture baseline severity, previous ideation or attempts, initiation and titration, behavioural activation, agitation, other psychiatric treatment and outcome.
Antidepressants may precipitate mania or hypomania in susceptible patients. A suspected event should be evaluated against the underlying bipolar history, sleep deprivation, substance exposure, dose changes and competing causes. The absence of a documented bipolar diagnosis is not the same as proof that a mood switch was caused by trazodone.
Cardiovascular safety: QT, syncope and falls
Trazodone prolongs the QT/QTc interval, and postmarketing reports include torsades de pointes and ventricular tachycardia. Current US labelling cautions against use in patients with known QT prolongation, relevant cardiac disease or concomitant QT-prolonging drugs and CYP3A4 inhibitors [1]. A case with syncope requires assessment of both rhythm disturbance and orthostatic hypotension; these mechanisms are not interchangeable.
The case record should obtain ECG tracings or reports, QTc correction method, potassium and magnesium values, dose, time of last administration, other QT-active medicines, renal or hepatic disease and whether an arrhythmia was objectively confirmed. QT prolongation alone does not prove torsades; conversely, the absence of an ECG may leave a clinically serious report unresolved.
Alpha-1 blockade can cause postural hypotension, dizziness and fainting. Older patients, patients on antihypertensives and people with frailty may be especially vulnerable to injury from falls. The downstream harm—fracture, head injury or hospitalisation—must be recorded in addition to the suspected initiating reaction.
Priapism: a distinctive serious risk
Priapism is a well-established, potentially tissue-damaging adverse reaction to trazodone. The US label advises that an erection lasting more than four hours, whether painful or not, warrants stopping the drug and emergency medical attention [1]. This is not an event that should be managed by watchful waiting in a routine pharmacovigilance workflow.
Follow-up should document onset, duration, pain, dose, concomitant erectile-dysfunction medicines, haematological conditions, prior episodes, emergency interventions and long-term function. The event may occur at doses used for sleep; it is therefore inappropriate to assume that off-label low-dose exposure eliminates the risk. Seriousness and outcome need medical assessment rather than relying only on the reporter's chosen term.
Serotonin syndrome and interaction-driven toxicity
Serotonin syndrome can occur during trazodone treatment and is more likely with other serotonergic drugs, including certain antidepressants, opioids and medicines affecting serotonin metabolism. US labelling contraindicates coadministration with monoamine oxidase inhibitors and specifies switching intervals [1]. The clinical picture includes neuromuscular, autonomic and mental-status abnormalities. A report of sweating and nausea alone is not sufficient to confirm the syndrome.
A robust narrative records exposure chronology, co-medications, examination findings such as clonus or hyperreflexia, temperature, vital signs, management and alternative diagnoses. Interaction reviews should distinguish a pharmacodynamic combination from a pharmacokinetic increase in trazodone exposure due to CYP3A4 inhibition.
Hyponatraemia and the 2025 safety-label update
Hyponatraemia, sometimes associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH), is a labelled risk. Older patients, those taking diuretics and patients who are volume-depleted may be more vulnerable [1]. An important lifecycle development occurred in 2025: the FDA notified the sponsor of Raldesy of new safety information concerning SIADH and approved a supplemental labelling revision [16]. The existence of a label update does not, by itself, establish an incidence rate or prove that every case of low sodium is caused by trazodone.
A suspected case should capture baseline and serial sodium, symptoms, fluid status, diuretics and other causative medicines, serum and urine osmolality where available, treatment and recovery. Severe hyponatraemia can present with seizures or altered consciousness; the clinical syndrome, not just the numerical laboratory result, determines medical urgency.
Bleeding, hepatic injury and additional risks
Serotonin reuptake interference may contribute to bleeding, particularly with aspirin, NSAIDs, anticoagulants or antiplatelet agents. Report assessment requires bleeding site, severity, objective findings, co-medications and baseline risk factors [1].
Trazodone has also been linked to rare clinically apparent liver injury, including severe cases. The NIH LiverTox review distinguishes generally modest asymptomatic liver-test elevations from idiosyncratic hepatitis and rare liver failure [17]. A suspected DILI case needs dated ALT, AST, bilirubin and alkaline phosphatase, competing causes, other medicines and dechallenge. Do not equate all elevated transaminases with liver failure.
Other labelled concerns include sedation and cognitive/motor impairment, angle-closure glaucoma in susceptible eyes, discontinuation symptoms, and the potential for clinically important interactions with central nervous system depressants. Risk assessment must reflect the exact product and population.
Regional labelling and formulation-specific questions
A UK Summary of Product Characteristics for trazodone capsules includes anxiety, depression and mixed anxiety–depression among its authorised indications, whereas current US immediate-release tablet and oral-solution labelling is framed around MDD in adults [1,18]. The UK document also gives different dosing and contraindication details. The United Kingdom is not a proxy for all European Union countries, and a US label is not an EU-wide marketing authorisation. A pharmacovigilance reviewer should retrieve the specific country's current SmPC rather than extrapolate from one jurisdiction.
For Raldesy oral solution, the concentration is 10 mg/mL. Confusing millilitres and milligrams can cause a tenfold or larger dosing error. The 2026 DailyMed record contains product-specific instructions for dosing devices and storage after opening [7]. A medication-error case should document the prescribed dose, measured volume, device, patient or caregiver training, dispensed formulation and actual ingestion. Do not apply a storage interval from an older label version without verifying the current one.
Pregnancy, lactation and special populations
Pregnancy and lactation assessment should follow the exact locally authorised label and the clinical context. Spontaneous reports cannot establish teratogenicity rates without denominators and adjustment for maternal illness and co-medication. A pregnancy-exposure case needs gestational timing, dose, other treatments, maternal outcomes, delivery information and infant follow-up, with appropriate privacy safeguards.
Older adults may have greater vulnerability to orthostatic hypotension, falls, sedation and hyponatraemia. Hepatic impairment is relevant because trazodone is extensively metabolised. Paediatric use is not approved under the current US product labels [1]. The correct interpretation is population- and jurisdiction-specific, not that the same risks have been quantified in every age group.
Pharmacovigilance cases: from observation to assessment
Case A: fall after a bedtime dose
Illustrative scenario, not an actual report. A frail patient starts trazodone for insomnia and falls on standing overnight. The initial report may list only a hip fracture. Follow-up should reconstruct time of dose, time of fall, postural symptoms, blood pressure, sedatives, antihypertensives, alcohol use and the extent of injury. The medical review distinguishes possible orthostatic hypotension, sedation and environmental causes; none should be asserted without supporting facts.
Case B: prolonged erection after low-dose exposure
Illustrative scenario. A patient receiving trazodone for sleep develops a prolonged erection and requires emergency treatment. The pharmacovigilance record must include duration, management, tissue injury and longer-term outcome. The suspected event may be medically serious even when the patient was not taking an antidepressant-range dose. The case should also capture co-exposures and underlying predispositions.
Case C: new hyponatraemia
Illustrative scenario. An older adult taking a thiazide diuretic develops confusion and severe hyponatraemia shortly after trazodone initiation. Follow-up should gather prior sodium values, both drugs' timing, fluid balance, laboratory assessment for SIADH, treatment and outcome. The diuretic is an important alternative or contributing cause; attributing the case solely to trazodone would exceed the evidence.
Signal detection, risk governance and inspection readiness
For a mature, widely used generic medicine, spontaneous-report counts alone cannot estimate the incidence of priapism, arrhythmia or falls. Exposure denominators, reporting stimulation, coding changes and the prevalence of off-label insomnia prescribing all influence the observed data. A signal review should specify its case definition and stratify by indication, formulation, dose, age, co-medications and relevant pre-existing conditions.
A product-specific safety review should distinguish legal requirements, labelled precautions, professional guidance and recommended internal practice. For example, a structured follow-up template for QT events is a useful quality practice; it is not a universal statutory requirement. EU or UK case-reporting and signal-management obligations must be checked against the relevant legal framework and authorisation rather than inferred from a US label.
Inspection-ready records should preserve the original report, coding, chronology, medical assessment, follow-up attempts, literature and regulatory source versions, escalation decisions and documented outcome of any safety action.
Practical review checklist
- Verify the exact INN, brand, dosage form, strength, country and current product-information revision.
- Record whether the actual indication is depression, anxiety or off-label insomnia; do not assume that prescribing prevalence establishes authorisation.
- Reconstruct dose and timing, including any switch between immediate-release, extended-release or oral-solution products.
- For syncope or arrhythmia, obtain ECG, electrolytes, orthostatic measurements, other QT-active drugs and injury outcome.
- For priapism, document duration, emergency intervention, concomitant exposures and functional outcome.
- For serotonin syndrome, seek neuromuscular findings, temperature, interacting medicines and alternative diagnoses.
- For hyponatraemia, capture baseline and serial sodium, diuretics, fluid status and diagnostic assessment.
- For suicidality, document baseline psychiatric history, initiation or titration, behavioural change and clinical management.
- For liver injury, seek a full biochemical chronology and competing causes.
- Distinguish case facts, medical interpretation, current regulatory requirements and internal risk-management practices.
Key takeaways
Trazodone's development spans Italian antidepressant research, US approval in 1981, reformulated once-daily treatment and a newer oral solution. Its broad clinical use for insomnia should not be mistaken for an FDA-approved hypnotic indication or strong evidence of long-term insomnia efficacy. Safety priorities include suicidality, orthostatic hypotension and falls, QT-related arrhythmia, priapism, serotonin syndrome, hyponatraemia and rare liver injury. Precise documentation of indication, dose, formulation and co-medications is essential to interpreting real-world safety reports.
References
- National Library of Medicine. DailyMed: trazodone hydrochloride tablets, US prescribing information, revised February 2026. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1510cf89-a2ec-4ed5-80cb-bae84f9ec0a7
- Fagiolini A, et al. Role of trazodone in treatment of major depressive disorder: an update. Ann Gen Psychiatry. 2023;22:32. https://pubmed.ncbi.nlm.nih.gov/37660092/
- Camargos EF, et al. Treatment of Alzheimer's disease: trazodone, sleep, serotonin, norepinephrine, and future directions. Front Pharmacol. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6398534/
- Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC3693429/
- US Food and Drug Administration. Raldesy: multidisciplinary review, NDA 218637, regulatory history. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218637Orig1s000MultidisciplineR.pdf
- Mead Johnson Pharmaceutical Group v. Bowen, 838 F.2d 1332 (DC Cir 1988), approval chronology. https://law.justia.com/cases/federal/appellate-courts/F2/838/1332/281256/
- National Library of Medicine. DailyMed: Raldesy oral solution, SPL effective September 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34708cc1-b0b2-4fd0-b9f3-7f008b457fc9
- Sheehan DV, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgmont). 2009. https://pubmed.ncbi.nlm.nih.gov/19724732/
- US Food and Drug Administration. Trazodone Contramid once daily: statistical review, NDA 022411. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022411s000StatR.pdf
- Fagiolini A, et al. Trazodone in MDD: comparative clinical trial evidence. Ann Gen Psychiatry. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10474647/
- Rediscovering trazodone: controlled comparative antidepressant trials. CNS Drugs. 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC3693429/
- US Food and Drug Administration. Oleptro (trazodone hydrochloride) extended-release prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022411lbl.pdf
- US Food and Drug Administration. Raldesy NDA 218637 original approval letter, 26 November 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218637Orig1s000Approv.pdf
- US Food and Drug Administration. Raldesy regulatory review: reliance on prior trazodone tablet findings. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218637Orig1s000OtherR.pdf
- Sateia MJ, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. J Clin Sleep Med. 2017;13:307–349. https://pmc.ncbi.nlm.nih.gov/articles/PMC5263087/
- US Food and Drug Administration. Raldesy NDA 218637/S-003 approval letter, 2025 SIADH safety-label revision. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218637Orig1s003ltr.pdf
- National Institutes of Health. LiverTox: Trazodone, updated 2020. https://www.ncbi.nlm.nih.gov/books/NBK548557/
- UK electronic Medicines Compendium. Trazodone hydrochloride 100 mg capsules: Summary of Product Characteristics, updated February 2026. https://www.medicines.org.uk/emc/product/13434/smpc
Regulatory Note
This article is an educational reference, not a prescribing recommendation. Regulatory claims are product- and jurisdiction-specific. FDA-labelled MDD treatment, UK indications and off-label insomnia use must not be conflated. Clinical trial results, observational safety reports, regulatory obligations and recommended pharmacovigilance procedures have different evidentiary status. Consult current authorised local product information before clinical or regulatory action.